Morgan Stanley has doubled down on Advanced Micro Devices (AMD), arguing the chipmaker can keep stealing server central processing unit (CPU) market share from Intel for years to come. In a research note, the bank lifted its 2027 server CPU revenue growth forecast for AMD to 100% and pushed out the timeline for Intel to reach technical parity to the second half of 2028.
The call is a clear bet that AMD's recent gains in the data-center chip market are not a one-off cycle but a sustained shift. Morgan Stanley also raised its longer-term earnings estimate for AMD, now projecting $18.77 in adjusted earnings per share for fiscal 2027, up from a prior $15.64. The bank bumped its price target to $550 from $510, a level that was well above the stock's recent price of around $483.58.
Why AMD keeps winning
Server CPUs are the brains of data-center servers, handling the heavy computing tasks that power everything from cloud services to artificial intelligence. For years, Intel dominated this market, but AMD has been chipping away at that lead with more efficient and powerful chips. Morgan Stanley's note argues that strong demand for data-center chips is giving AMD room to expand its share even while supply chains remain tight.
The bank expects next year's unit growth to skew toward AMD, with Intel losing a similar amount of share. Product timing is a key swing factor, as customers line up future orders based on when each company's next-generation chips will be available. If AMD can deliver its chips on schedule while Intel's roadmap slips, the share gains could accelerate.
This is not just about who sells more processors. It is about the profit potential that comes with each percentage point of market share. Server CPUs are high-margin products, and winning in this segment can have an outsized impact on a chipmaker's bottom line.
What it means for investors
Morgan Stanley's new price target implies a forward price-to-earnings (P/E) ratio of roughly 29 times its 2027 earnings forecast of $18.77. At the stock's recent price near $483.58, the implied P/E is closer to 26 times on the same earnings base. That gap shows where expectations are sitting: the bank's upside case assumes both higher earnings and a slightly richer valuation multiple.
For everyday investors, this is a reminder that a stock's price reflects not just expected profits but also how much investors are willing to pay for those profits. If AMD hits the 2027 earnings track, that "multiple expansion" can boost returns. But if results fall short, the stock can suffer a double hit—lower earnings and a less generous multiple—even if the longer timeline for Intel to catch up remains intact.
The broader context is that AI and cloud computing are driving explosive demand for data-center hardware. Companies like Super Micro have also flagged strong AI server demand, and raised their own 2027 outlooks. That backdrop supports the idea that AMD's growth runway could be longer than some investors expect.
Risks to the bull case
Morgan Stanley's view is not without risks. Intel is not standing still—it has its own roadmap and a massive installed base. If Intel's product timing improves, the parity timeline could move up, undercutting AMD's share gains. Supply chain constraints, which the bank acknowledges, could also limit AMD's ability to ship as many chips as demand warrants.
Valuation is another concern. At 26 to 29 times forward earnings, AMD is not cheap. If the broader market turns risk-off or if AMD's growth slows, the multiple could compress quickly. Investors should also remember that analyst price targets are opinions, not guarantees.
For those watching the chip sector, the key metrics to track are AMD's quarterly server CPU revenue growth, Intel's product launch dates, and any commentary from data-center customers about their purchasing plans. The next earnings reports from both companies will offer fresh clues.
Morgan Stanley's move is a notable endorsement of the "share gains" story, but it is also a bet on a specific timeline. If AMD delivers on the 2027 earnings path, the stock could reward patient investors. If not, the downside could be just as pronounced.
